Rain Therapeutics is a clinical-stage precision oncology company, with the mission to develop the best precision oncology therapies for patients suffering from cancer.
Total raised: $118M
Founded date: 2017
Investors 2
| Date | Name | Website |
| 19.11.2020 | Logos Capi... | logoscapit... |
| - | Perceptive... | perceptive... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 12.04.2021 | IPO | $100M | - |
| 21.05.2018 | Series A | $18M | - |
Mentions in press and media 4
| Date | Title | Description |
| 04.09.2020 | Rain bags $63M, ex-Daiichi cancer drug to mount pivotal push | Rain Therapeutics has raised $63 million and licensed a Daiichi Sankyo cancer drug to accelerate its progress into pivotal development. Licensing the ex-Daiichi small molecule sets Rain up to go after a target a who’s who of leading drug de... |
| 04.09.2020 | Rain bags $63M, ex-Daiichi cancer drug to mount pivotal push | Rain Therapeutics has raised $63 million and licensed a Daiichi Sankyo cancer drug to accelerate its progress into pivotal development. Licensing the ex-Daiichi small molecule sets Rain up to go after a target a who’s who of leading drug de... |
| 21.05.2018 | Rain Therapeutics scores $18 million Series A round for lung cancer drug | Rain plans to use its funding to start a Phase II clinical trial of tarloxotinib in the first half of 2019. The trial will include patients with non-small cell lung cancer whose disease exhibits EGFR and ErbB Exon 20 mutations. Despite expr... |
| - | Rain Therapeutics scores $18 million Series A round for lung cancer drug | A company developing a drug for a hard-to-treat form of lung cancer has secured a funding round worth more than $18 million. Fremont, California-based Rain Therapeutics said Monday that it had closed an $18.4 million Series A round led by t... |